Can You Buy Retatrutide? What the FDA Databases Actually Show

Retatrutide is not approved by the FDA and cannot be legally sold in the United States for human use. It is an investigational drug in phase 3 trials.

That is the short answer, and it is not the useful part. The useful part is why the sellers offering it look legitimate, because the paperwork they can show you is real.

What the two FDA systems say

There are two databases worth checking, and they say different things.

Drugs@FDA: no application at all

Drugs@FDA is the register of approved drugs. Searching it for retatrutide returns nothing — not a pending application, not a rejected one. There is no approval record because no approval has been sought and granted.

For comparison, orforglipron appears there as application NDA 220934, sponsor Eli Lilly, approved 1 April 2026. That is what an approved drug looks like in that system. Retatrutide has no equivalent entry.

DailyMed: ten product listings

Here is where it gets complicated. DailyMed, the National Library of Medicine's drug labelling database, carries ten retatrutide product listings. All ten were filed by a single company — a cross-border e-commerce business registered in Guangzhou — and published on 17 November 2025.

They are specific, which is what makes them convincing:

• Pens at 10 mg, 30 mg and 40 mg
• Lyophilised powder at 2.5 mg, 5 mg, 7.5 mg and 10 mg
• Branded SALKALLI

Each has a label, a set identifier and a publication date, exactly as an approved drug does.

Why a DailyMed listing is not an approval

This is the distinction the entire grey market rests on, and almost nobody has been told it exists.

Listing a drug and approving a drug are different processes. Listing is a registration step: a company tells the FDA that a product exists and submits labelling for it. Approval is a review of whether the drug is safe and effective for its intended use, involving clinical data, manufacturing inspection and years of assessment.

DailyMed publishes submitted labelling. It is a labelling repository, not a verdict.

So a seller can send you a link to a real page, on a real government-run database, showing a real label with real dose strengths printed on it. Every one of those words is accurate. And none of it means the FDA has assessed the drug, the manufacturer, or the contents of the vial.

Nothing on that page has verified that what arrives contains retatrutide, that it contains the stated amount, or that it is sterile.

What "research peptide" actually means

Retatrutide is sold online almost entirely under the research-chemical framing: labelled "for research use only", "not for human consumption", sold as a peptide rather than as a medicine.

That wording is doing legal work, not safety work. It is what allows the sale to sit outside the framework that governs medicines — and the same wording is why nothing about the product carries the obligations a medicine carries.

Specifically, and this is the part worth sitting with:

• No identity testing. Nothing establishes that the powder is retatrutide rather than a different peptide, or a mixture.
• No potency testing. A vial labelled 10 mg may contain more, less, or none.
• No sterility assurance. This is an injectable. Sterility is not a quality nicety.
• No pharmacovigilance. If something goes wrong, there is no reporting channel and no recall mechanism, because the product is not a medicine in any system that could recall it.
• No dosing guidance from anyone accountable. Retatrutide's trial dosing exists in the trial protocols. What is circulating in forums is not that.

What retatrutide actually is

The interest is not irrational, which is worth saying plainly. Retatrutide is a triple agonist — it acts on GLP-1, GIP and glucagon receptors, where tirzepatide acts on two and semaglutide on one. Early trial results have shown weight loss in the high-20% range, above anything currently approved.

If it completes its programme and is approved, it will likely be the most effective obesity drug available. That is a real prospect and a reasonable thing to want.

It is also not what is in an unregulated vial. See the newest GLP-1 drugs and retatrutide for where the trial programme stands.

The legitimate route

A clinical trial is the only lawful way to receive retatrutide in the United States today.

Trials are actively recruiting, they are free to participants, and they come with monitoring that no online seller offers. The trade-off is real — you may receive placebo, and you must meet eligibility criteria — but it is the only route where somebody is accountable for what you are injecting.

Registries of recruiting trials are public and searchable by condition and location.

If you want the effect now, there are approved options

Three drugs are approved for chronic weight management and available on prescription:

• Zepbound (tirzepatide) — a dual GLP-1/GIP agonist, roughly 20.9% mean weight loss over 72 weeks in SURMOUNT-1.
• Wegovy (semaglutide) — roughly 14.9% over 68 weeks in STEP-1, and now available as a tablet as well as an injection.
• Foundayo (orforglipron) — the first oral small-molecule GLP-1, approved 1 April 2026, 11.1% at the maximum dose.

Retatrutide's trial numbers are higher than all three. They are also unverifiable in anything you can buy today, which makes the comparison meaningless in practice. See GLP-1 weight loss results by drug.

This article is general information, not medical or legal advice. The database checks described were made on 4 August 2026 against Drugs@FDA and DailyMed and reflect what those systems held on that date; both change. Nothing here should be read as guidance on obtaining an unapproved drug. Discuss any weight-management medication with a qualified clinician, and treat trial-stage results as provisional until a drug completes review.